Unknown

Dataset Information

0

HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging.


ABSTRACT: The human epidermal growth factor receptors, EGFR and HER2, are members of the EGFR family of cell-surface receptors/tyrosine kinases. EGFR- and HER2-positive cancers represent a more aggressive disease with greater likelihood of recurrence, poorer prognosis, and decreased survival rate, compared to EGFR- or HER2-negative cancers. The details of HER2 proto-oncogenic functions are not deeply understood, partially because of a restricted availability of tools for EGFR and HER2 detection (A. Sorkin and L. K. Goh, Exp. Cell Res. 2009, 315, 683-696). We have created photostable and relatively simple-to-produce imaging probes for in vitro staining of EGFR and HER2. These new reagents, called affiprobes, consist of a targeting moiety, a HER2- or EGFR-specific Affibody molecule, and a fluorescent moiety, mCherry (red) or EGFP (green). Our flow cytometry and confocal microscopy experiments demonstrated high specificity and signal/background ratio of affiprobes. Affiprobes are able to stain both live cells and frozen tumor xenograph sections. This type of optical probe can easily be extended for targeting other cell-surface antigens/ receptors.

SUBMITTER: Lyakhov I 

PROVIDER: S-EPMC3092587 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging.

Lyakhov Ilya I   Zielinski Rafal R   Kuban Monika M   Kramer-Marek Gabriela G   Fisher Robert R   Chertov Oleg O   Bindu Lakshman L   Capala Jacek J  

Chembiochem : a European journal of chemical biology 20100201 3


The human epidermal growth factor receptors, EGFR and HER2, are members of the EGFR family of cell-surface receptors/tyrosine kinases. EGFR- and HER2-positive cancers represent a more aggressive disease with greater likelihood of recurrence, poorer prognosis, and decreased survival rate, compared to EGFR- or HER2-negative cancers. The details of HER2 proto-oncogenic functions are not deeply understood, partially because of a restricted availability of tools for EGFR and HER2 detection (A. Sorkin  ...[more]

Similar Datasets

| S-EPMC5217050 | biostudies-literature
| S-EPMC2830426 | biostudies-literature
| S-EPMC4751542 | biostudies-literature
| S-EPMC3402039 | biostudies-literature
| 2632761 | ecrin-mdr-crc
| S-EPMC6128814 | biostudies-literature
| S-EPMC4871752 | biostudies-literature
| S-EPMC5134568 | biostudies-literature
| S-EPMC10803022 | biostudies-literature
| S-EPMC6486219 | biostudies-literature